How to choose initial treatment in multiple sclerosis patients: a case-based approach

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Immunotherapy has transformed multiple sclerosis (MS) management, shifting focus from disability to early disease control.
• While high-efficacy treatments offer benefits, safety concerns necessitate careful consideration in clinical practice.
• Selecting appropriate disease-modifying therapies for MS remains a complex challenge for clinicians.

Purpose of the Study:

• To review current strategies for selecting initial therapies in patients with relapsing multiple sclerosis (MS).

Main Methods:

• A case-based approach was employed, integrating clinical discussions to explore therapeutic options.
• Therapeutic options were analyzed within various multiple sclerosis (MS) treatment contexts.

Main Results:

• Clinical case profiles were presented, illustrating the application of moderate- and high-efficacy MS therapies.
• Moderate efficacy options included interferons, glatiramer acetate, teriflunomide, and dimethyl fumarate.
• High efficacy options discussed were fingolimod, cladribine, natalizumab, ocrelizumab, alemtuzumab, and ofatumumab.

Conclusions:

• Significant advancements in multiple sclerosis (MS) treatment underscore the value of early, high-efficacy therapeutic approaches.
• Personalized treatment decisions should integrate prognostic factors, including biomarkers, clinical, and radiological data, with individual patient considerations.